Original articleIntensive chemotherapy of poor prognosis myelodysplastic syndromes (MDS) and acute myeloid leukemia following MDS with idarubicin and cytarabine
References (25)
Intensive chemotherapy in myelodysplastic syndromes
Blood Rev.
(1992)- et al.
Prognostic factors in myelodysplastic syndromes
Leukemia Res.
(1992) - et al.
Intensive chemotherapy and bone marrow transplantation for myelodysplastic syndromes
Hematol Oncol. Clin. N. Am.
(1992) - et al.
Influence of idarubicinol on the antileukemic effect of idarubicin
Leukemia Res.
(1994) - et al.
Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells
Blood
(1992) - et al.
Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia
Blood
(1991) - et al.
A randomized clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute nonlymphoid leukemia
Euro. J. Cancer
(1991) - et al.
Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia
Blood
(1992) - et al.
Bone marrow transplantation for myelodysplastic syndrome and secondary leukaemias
Br. J. Haematol.
(1993) - et al.
Clinical course of myelodysplastic syndromes
Hematol. Oncol. Clin. N. Am.
(1992)
The role of intensive chemotherapy in myelodysplastic syndromes
Leukemia and Lymphoma
(1992)
Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months' duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG)
Leukemia
(1995)
Cited by (32)
Hematopoietic stem cell transplantation for MDS
2010, Hematology/Oncology Clinics of North AmericaThe myelodysplastic syndromes: Diagnosis and treatment
2006, Mayo Clinic ProceedingsCitation Excerpt :The 40% to 50% of patients with MDS who are short-term responders in clinical trials of chemotherapy regimens are usually a selected group, younger and healthier than the typical older patient with aggressive MDS. Almost all patients with MDS who achieve remission via chemotherapy promptly experience relapse.268–270 Only about 5% of patients who receive high-dose therapy are alive at 3 years, but there are occasional long-term responders.271
Nucleoside analogs and antimetabolite therapies for myelodysplastic syndrome
2004, Best Practice and Research: Clinical HaematologyThe myelodysplastic syndrome(s): A perspective and review highlighting current controversies
2003, Leukemia ResearchEnergy metabolism and drug response in myeloid leukaemic stem cells
2019, British Journal of HaematologyCharacterization and targeting of malignant stem cells in patients with advanced myelodysplastic syndromes
2018, Nature Communications
Copyright © 1997 Published by Elsevier Ltd.